Citi raised CSPC Group's profit forecast and target price, saying that its third-quarter results exceeded expectations, thanks to increased licensing revenue and core business recovery. Analyst John Yung and others said in the report that in view of the better-than-expected growth rate of drug sales, the 2026 revenue and net profit forecasts for the 2026 fiscal year were raised by 2% and 3%, respectively. More than 10 new products/new indications are expected to be approved for launch next year, providing solid support for management's expectations for positive overall growth. The target price was raised from HK$14.6 to HK$15 and the “Buy” rating was maintained.

Zhitongcaijing · 2d ago
Citi raised CSPC Group's profit forecast and target price, saying that its third-quarter results exceeded expectations, thanks to increased licensing revenue and core business recovery. Analyst John Yung and others said in the report that in view of the better-than-expected growth rate of drug sales, the 2026 revenue and net profit forecasts for the 2026 fiscal year were raised by 2% and 3%, respectively. More than 10 new products/new indications are expected to be approved for launch next year, providing solid support for management's expectations for positive overall growth. The target price was raised from HK$14.6 to HK$15 and the “Buy” rating was maintained.